Gout is a disabling and common illness in Europe with a prevalence rate of 0.9% to 2.5% . However, it still remains misdiagnosed in most of the cases and thus the management remains suboptimal inspite of various effective treatments available. For efficient diagnosis, the first European League Against Rheumatism (EULAR) recommendations for the management of gout was formulated in 2006, which was based on a systematic literature review (SLR) and expert opinions. Back in 2006, the number of drugs available for the gout treatment were limited and the main urate-lowering therapy (ULT) available was allopurinol. Till now, many drugs are available in late-stage of development (example- febuxostat, pegloticase, interleukin-1 (IL-1) blockers, lesinurad).